PubRank

Philip E Aylward

Author PubWeight™ 52.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 5.49
2 Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012 4.49
3 Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2011 3.20
4 Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014 2.90
5 Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002 2.23
6 2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung Circ 2011 1.71
7 Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation 2007 1.67
8 Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. Am J Cardiol 2002 1.60
9 Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J 2013 1.56
10 High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005 1.52
11 Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation 2011 1.43
12 The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J 2006 1.10
13 A randomised study of three different informational AIDS prior to coronary angiography, measuring patient recall, satisfaction and anxiety. Heart Lung Circ 2007 1.05
14 Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv 2008 1.02
15 Prognostic value of lead V1 ST elevation during acute inferior myocardial infarction. Circulation 2010 0.96
16 Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. Am Heart J 2005 0.88
17 Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010 0.86
18 Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovasc Interv 2010 0.86
19 Plasma surfactant protein-B: a novel biomarker in chronic heart failure. Circulation 2004 0.86
20 Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol 2008 0.85
21 Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013 0.85
22 QRS duration alone misses cardiac dyssynchrony in a substantial proportion of patients with chronic heart failure. J Am Soc Echocardiogr 2006 0.84
23 Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Eur Heart J 2008 0.83
24 Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur Heart J 2008 0.83
25 Coronary artery wall thickness of the left anterior descending artery using high resolution transthoracic echocardiography--normal range of values. Echocardiography 2013 0.83
26 Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Circ Cardiovasc Qual Outcomes 2011 0.82
27 Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. Am Heart J 2010 0.82
28 Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med 2008 0.82
29 Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Am Heart J 2010 0.81
30 Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv 2010 0.81
31 Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol 2008 0.81
32 High-resolution transthoracic echocardiography of the left anterior descending coronary artery: a novel noninvasive assessment of coronary vasoreactivity. J Am Soc Echocardiogr 2007 0.80
33 Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. Am Heart J 2008 0.80
34 Changes in left anterior descending coronary artery wall thickness detected by high resolution transthoracic echocardiography. Am J Cardiol 2008 0.79
35 The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Curr Opin Cardiol 2010 0.79
36 Outcomes of cardiac surgery in Indigenous Australians. Med J Aust 2009 0.78
37 Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol 2013 0.78
38 Predictors of statin-induced regression of left anterior descending coronary artery wall thickness as measured by high-resolution transthoracic echocardiography. Echocardiography 2012 0.77
39 Practical experience with ticagrelor: an Australian and New Zealand perspective. Curr Med Res Opin 2015 0.77
40 Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis 2008 0.76
41 Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis 2012 0.75
42 The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. Am Heart J 2008 0.75
43 New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clin Ther 2013 0.75